Advanced search
Publication Cover
Gynecological Endocrinology Volume 39, 2023 - Issue 1
Submit an article Journal homepage
2,554
Views
2
CrossRef citations to date
0
Altmetric
Research Article

NOMAC-E2 compares to LNG combined oral contraceptives in women over forty: real-world PRO-E2 study

Sophia von Stockuma Berlin Center for Epidemiology and Health Research (ZEG), Berlin, GermanyView further author information
,
Kerstin Beckera Berlin Center for Epidemiology and Health Research (ZEG), Berlin, GermanyView further author information
,
Anja Bauerfeinda Berlin Center for Epidemiology and Health Research (ZEG), Berlin, GermanyView further author information
,
Christian Frankea Berlin Center for Epidemiology and Health Research (ZEG), Berlin, GermanyView further author information
,
Franca Fruzzettib Department of Obstetrics and Gynecology, Pisa University Hospital, Pisa, ItalyView further author information
,
Joaquim Calafc Department of Obstetrics and Gynaecology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-2407-7884View further author information
ORCID Icon,
Christoph Keckd amedes MDL, Hamburg, GermanyView further author information
&
Klaas Heinemanna Berlin Center for Epidemiology and Health Research (ZEG), Berlin, GermanyCorrespondence[email protected]
View further author information
 show all
Article: 2166032 | Received 08 Aug 2022, Accepted 03 Jan 2023, Published online: 23 Jan 2023

References

  • Harlow S D, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):1–5.
  • Santoro N. Perimenopause: from research to practice. J Womens Health (Larchmt). 2016;25(4):332–339.
  • Shaaban MM. The perimenopause and contraception. Maturitas. 1996;23(2):181–192.
  • Kailas NA, Sifakis S, Koumantakis E. Contraception during perimenopause. Eur J Contracept Reprod Health Care. 2005;10(1):19–25.
  • Cho MK. Use of combined oral contraceptives in perimenopausal women. Chonnam Med J. 2018;54(3):153–158.
  • Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96(6):913–920.
  • Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31(1):66–70.
  • Mendoza N, Soto E, Sánchez-Borrego R. Do women aged over 40 need different counseling on combined hormonal contraception? Maturitas. 2016;87:79–83.
  • Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for contraceptive use. 2016 (July 29, 2016).
  • Faculty of Sexual & Reproductive Healthcare. FSRH Guideline Contraception for women aged over 40 years. August 2017. (Amended September 2019).
  • Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas. 2012;71(4):345–353.
  • European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) – Module VIII – Post-authorisation safety studies (Rev. 3). 2017.
  • Reed S, Koro C, DiBello J, et al. Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study. Eur J Contracept Reprod Health Care. 2021;26(6):447–453.
  • Reed S, Koro C, DiBello J, et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021;26(6):439–446.
  • Arner P, Bernard S, Appelsved L, et al. Adipose lipid turnover and long-term changes in body weight. Nat Med. 2019;25(9):1385–1389.
  • Gebbie A. Contraception in the perimenopause. J Br Menopause Soc. 2003;9(3):123–128.
  • Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78(1):16–25.
  • Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-Centre study. Clin Drug Investig. 2011;31(8):573–584.
  • Fruzzetti F, Trémollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28(5):400–408.
  • Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol. 1991;133(7):635–648.
  • Read CM. New regimens with combined oral contraceptive pills–moving away from traditional 21/7 cycles. Eur J Contracept Reprod Health Care. 2010;15 Suppl 2: s 32–41.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.